Acrivon Therapeutics held a Key Opinion Leader (KOL) panel to discuss interim data from its ACR-368 Phase 2b registrational-intent trial for endometrial cancer. ACR-368 is a potent, selective CHK1/2 inhibitor, with patient selection guided by the OncoSignature biomarker test. In Arm 1 (BM+), the Objective Response Rate (ORR) was 39% (95% CI, 24-56) in patients with high-grade EC and 3 prior lines of therapy. A higher ORR of 44% (95% CI, 27-63) was observed in BM+ patients with 2 prior lines of therapy. For the serous all-comer population with 2 or more prior lines of therapy, ACR-368 demonstrated a significant ORR of 52% (95% CI, 33-71). The drug exhibited a favorable safety profile, with limited, transient, mechanism-based hematological adverse events and a notable absence of severe GI, pulmonary, or neurological toxicities. The study is expanding to over 20 sites in four major EU countries, with enrollment completion anticipated by Q4 2026.